Maintaining Roche's FVE After Solid 3Q; Shares Continue to Incorporate Bearish Pipeline Projection
Roche reported third-quarter sales that slightly beat consensus expectations but were in line with our estimates, and we're adjusting our fair value estimate slightly to $42/CHF 333 to account for minor sales forecast and exchange rate changes. The third quarter was Roche's second consecutive quarter with 7% constant-currency top-line growth, driven by solid performance in both pharmaceutical (7%) and diagnostics (6%) segments. On biosimilars, we're encouraged by increased clarity on the timing ...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.